Dr Jay: Corporate Strategy- 1 or two studies (CRC and Inflammation in HIV) to be initiated in the next 6 months. CRC based on work of Dr Dan Linder of LL at Mayo and basket trial data. Protocol with an established regimen.

Inflammation study, what biomarkers and how does LL impact Inflammation in non HIV setting? What is the best dosing? CRP and other biomarkers for Inflammation to be measured.